Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2006

View Archived Issues

Plans for clinical investigation of low-dose cortisol for chronic PTSD

huC242-DM4 appears safe in phase I study

Assay predicts response to imatinib in CML patients

Antiarthritic potential of the novel ADAM inhibitor S-44029 demonstrated in vitro

NDA filed for Zingo needle-free local anesthetic

Milk thistle components suppress the growth of colon cancer cells

Snapshots on novel targets in autosomal dominant polycystic kidney disease

Codevelopment agreements terminated for HFT-290 and NS-126

Positive results for Atopiclair in pediatric atopic dermatitis

Inex clears another hurdle towards spin-out of Tekmira

A-831 begins phase I for hepatitis C

Mayne Pharma to acquire remaining worldwide rights to Nipent

Sanofi-aventis reflects on Q3 achievements

Promising preliminary clinical results for Aegerion's novel MTP inhibitor

Myocardial protection from postconditioning may be mediated by adenosine A2B receptors

New anticancer agents imparted in recent patents

Recent patent literature reports new therapeutic agents insomnia, anxiety, etc.

Novel PDE4 inhibitors patented by Boehringer Ingelheim, Ranbaxy

New antiarthritic compounds discovered according to recent patents

MKC-1106-PP immunotherapy cleared for phase I study in solid malignancies

Enrollment complete in phase IIa bipolar disorder trial of MEM-1003

Positive interim findings for Cethrin in treatment of acute spinal cord injury

Treatment under way in phase III study of phenoxodiol in ovarian cancer

Halozyme completes enrollment in study of Enhanze Technology

Schering AG and Stanford University collaborate on molecular imaging

Organon and Pfizer discontinue asenapine collaboration

Further positive findings for AN-152 in gynecological and breast cancers

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...